Who
Sam L. Barker
Director
Company insider
Files Form 4 as: Director, Lexicon Pharmaceuticals; Director, Bio Green Med Solution; Director, Cadence Pharmaceuticals; Director, Atherogenics.
In numbers
- Trades disclosed
- 124
- Buys
- 9
- Sells
- 2
- Bought
- $294K
- Sold
- $1,083
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 15 Feb 2006
- Last trade
- 3 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —89,312 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,714 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,478 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,714 at $0.00 | filing |
| 1 May 2026filed 4 May 2026 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —43,478 at $0.00 | filing |
| 3 Jun 2025filed 3 Jun 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —103,806 at $0.00 | filing |
| 3 Jun 2025filed 3 Jun 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —89,312 at $0.00 | filing |
| 13 May 2025filed 13 May 2025 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —36,810 at $0.00 | filing |
| 13 May 2025filed 13 May 2025 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —36,810 at $0.00 | filing |
| 13 May 2024filed 13 May 2024 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,906 at $0.00 | filing |
| 13 May 2024filed 13 May 2024 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,810 at $0.00 | filing |
| 28 Apr 2024filed 29 Apr 2024 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,032 at $0.00 | filing |
| 28 Apr 2024filed 29 Apr 2024 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,032 at $0.00 | filing |
| 30 Jun 2023filed 3 Jul 2023 | BGMS Bio Green Med Solutionoption or derivative · Distributors & Wholesale | SEC FORM 4 Code A | —42,438 at $0.00 | filing |
| 30 Jun 2023filed 3 Jul 2023 | BGMS Bio Green Med SolutionDistributors & Wholesale | SEC FORM 4 Code A | —21,219 at $0.00 | filing |
| 21 May 2023filed 22 May 2023 | LXRX Lexicon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —9,302 at $0.00 | filing |
| 21 May 2023filed 22 May 2023 | LXRX Lexicon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —9,302 at $0.00 | filing |
News
Ashtead Group (OTCMKTS:ASHTY) versus Cyclacel Pharmaceuticals (NASDAQ:BGMS) Critical ReviewBGMS · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Sam L. Barker; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.